Table 6 Multivariate analysis of LR, RR, and DM of young breast cancer patients

Tumor size

< 0.01

0.11

0.01

T1

1.0

1.0

1.0

T2

0.5 (0.2–1.0)

0.05

0.6 (0.3–1.4)

0.24

1.4 (0.9–2.3)

0.16

T3

1.7 (0.6– 4.8)

0.33

1.2 (0.5–2.9)

0.74

1.8 (1.0–3.2)

0.04

T4

6.5 (1.2–36.9)

0.03

4.2 (1.0–17.2)

0.05

5.4 (2.0–14.0)

< 0.01

Stage

0.24

0.09

0.57

I

1.0

1.0

1.0

II a

1.7 (0.7–4.2)

0.22

0.5 (0.2–1.6)

0.26

1.4 (0.7–2.8)

0.28

II b

2.1 (0.6–7.8)

0.25

2.2 (0.6–8.8)

0.25

1.3 (0.5–3.4)

0.53

III a

0.7 (0.2–3.5)

0.69

0.9 (0.2–4.4)

0.90

2.1 (0.8–5.8)

0.15

III b

0.9 (0.1–9.0)

0.96

0.3 (0.0–4.8)

0.43

1.2 (0.3–4.9)

0.81

III c

0.5 (0.1–3.6)

0.53

0.2 (0.0–1.5)

0.11

4.2 (1.0–17.8)

0.05

LN metastasis

0.06

0.02

0.59

N0

1.0

1.0

1.0

N1

2.0 (1.0–4.0)

0.05

1.6 (0.6–4.1)

0.32

1.5 (0.9–2.6)

0.14

N2

1.01 (0.3–3.5)

0.93

7.1 (1.7–29.2)

< 0.01

1.3 (0.6–2.9)

0.50

N3

6.9 (1.4–35.0)

0.02

34.7 (4.0–304.1)

< 0.01

1.3 (0.3–4.7)

0.73

Final surgery

–

–

0.14

Mastectomy

–

–

1.0

BCS

–

–

–

–

0.7 (0.4–1.1)

0.14

ER status

0.70

–

–

Positive

1.0

–

–

Negative

1.5 (0.6–3.9)

0.40

–

–

–

–

PR status

0.54

–

–

Positive

1.0

–

–

Negative

1.5 (0.6–3.6)

0.41

–

–

–

–

HER2 status

0.92

–

–

Positive

1.0

–

–

Negative

0.0 (0.0–NA)

0.92

–

–

–

–

MS

0.49

–

0.01

HR+/HER2−

1.0

–

1.0

HR+/HER2+

0.0 (0.0–NA)

0.92

–

–

1.4 (0.9–2.1)

0.15

HR−/HER2+

0.0 (0.0–NA)

0.92

–

–

2.5 (1.5–4.4)

< 0.01

HR−/HER2−

0.3 (0.1–1.2)

0.10

–

–

1.9 (1.1–3.2)

0.02

NACT

0.57

0.11

0.04

No

1.0

1.0

1.0

Yes

1.2 (0.7–2.2)

0.57

1.6 (0.9–3.0)

0.11

1.4 (1.0–2.0)

0.04

Radiotherapy

–

0.10

0.64

No

–

1.0

1.0

Yes

–

–

0.5 (0.2–1.1)

0.09

1.2 (0.7–2.0)

0.41

ET

0.07

–

–

No

1.0

–

–

Yes

0.4 (0.2–1.0)

0.04

–

–

–

–

OFS

–

0.03

< 0.01

No

–

1.0

1.0

Yes

–

–

2.4 (1.2–4.6)

< 0.01

3.7 (2.3–5.8)

< 0.01